急性呼吸窮迫症候群の市場：タイプ、原因、エンドユーザー別-2025-2030年の世界予測

急性呼吸窮迫症候群市場は、2023年に25億6,000万米ドルと評価され、2024年には27億2,000万米ドルに達すると予測され、CAGR 6.13％で成長し、2030年には38億9,000万米ドルに達すると予測されています。

急性呼吸窮迫症候群（ARDS）は、肺の広範な炎症によって特徴づけられる、重篤で急速に発症する呼吸器疾患です。血液を酸素化する能力が低下し、多くの場合、機械的人工呼吸などのクリティカルケア支援を必要とします。ARDSに対処する必要性は、その高い死亡率と、世界の呼吸器疾患の有病率の増加から生じています。ARDSの調査と治療の応用はヘルスケア施設にまたがっており、主なエンドユーザーは病院と専門の呼吸ケアセンターです。最近の市場洞察では、人口の高齢化と慢性肺疾患の罹患率の上昇を背景に、先進的な換気装置、革新的な薬理療法、支持療法製品に対する需要の高まりが強調されています。主な成長要因としては、医療機器の技術進歩、医療費の増加、新興国におけるヘルスケアインフラの改善などが挙げられます。特筆すべきは、COVID-19の大流行が呼吸器ケアへの意識と投資を高め、ARDS管理のための遠隔医療と遠隔モニタリングソリューションに大きな機会をもたらしていることです。

個別の患者管理に画期的な進歩をもたらす可能性のある個別化医療アプローチと生物学的製剤の開発にチャンスがあります。しかし、市場は高い治療費、規制上のハードル、ARDSの病態生理の複雑さなどの制約に直面しており、普遍的に有効な治療法を開発するための課題となっています。また、早期発見・早期介入を確実にするための診断ツールの改善も急務です。非侵襲的換気技術、早期ARDSバイオマーカー、AIによる患者予後予測分析など、技術革新の機が熟している分野があります。ARDS市場はダイナミックで、デジタルヘルス技術の統合や、バイオテクノロジー企業、研究機関、ヘルスケアプロバイダー間の協力が進む傾向にあります。これを活用するため、企業は戦略的パートナーシップに注力し、新規治療ソリューションのための調査に投資すべきです。社会経済的障壁に対処し、患者の意識を高めることも、市場の存在感と成長を強化する上で役立つと思われます。

市場力学：急速に進化する急性呼吸窮迫症候群市場の主要市場インサイトを公開

急性呼吸窮迫症候群市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 敗血症、外傷、感染症の増加によるARDSの有病率の増加
  • 人工呼吸および支持療法の進歩
  • 新薬の研究開発への注目の高まり
• 市場抑制要因
  • 高い治療費と高度医療へのアクセス制限
• 市場機会
  • 個別化医療アプローチの継続的開発
  • 政府の取り組みとヘルスケア・インフラ投資の増加
• 市場の課題
  • 新しい治療法や機器の承認に関する規制の複雑さ

ポーターのファイブフォース：急性呼吸窮迫症候群市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：急性呼吸窮迫症候群市場における外部からの影響の把握

外部マクロ環境要因は、急性呼吸窮迫症候群市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析急性呼吸窮迫症候群市場における競合情勢の把握

急性呼吸窮迫症候群市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス急性呼吸窮迫症候群市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、急性呼吸窮迫症候群市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨急性呼吸窮迫症候群市場における成功への道筋を描く

急性呼吸窮迫症候群市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 敗血症、外傷、感染症の増加によりARDSの罹患率が上昇している
    • 人工呼吸器と支持療法の進歩
    • 新薬の研究開発への注目が高まる
  • 抑制要因
    • 治療費が高く、高度な医療へのアクセスが限られている
  • 機会
    • 個別化医療アプローチの継続的な開発
    • 政府の取り組みとヘルスケアインフラへの投資の増加
  • 課題
    • 新しい治療法や機器の承認に関する規制の複雑さ
• 市場セグメンテーション分析
  • タイプ：精密医療への応用の可能性により診断の必要性が高まっている
  • エンドユーザー：ARDSの管理における病院の優先性拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 急性呼吸窮迫症候群の市場：タイプ別

• 診断
• 治療

第7章 急性呼吸窮迫症候群の市場原因別

• 直接的な肺損傷
• 間接的な肺損傷

第8章 急性呼吸窮迫症候群の市場：エンドユーザー別

• 病院
• 専門クリニック

第9章 南北アメリカの急性呼吸窮迫症候群の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の急性呼吸窮迫症候群の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの急性呼吸窮迫症候群の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • バイオイージス、ARDS治療薬開発でBARDAと2,000万米ドルの契約を獲得
  • Veru Inc.、FDAとサビザブリンの第3相臨床試験で合意、適応症は拡大あらゆるタイプのウイルス性ARDSを患う入院成人患者
• 戦略分析と提言

企業一覧

• APEPTICO GmbH
• Armstrong Medical Ltd.
• Athersys, Inc.
• Bayer AG
• Besmed Health Business Corp.
• Dragerwerk AG & Co. KGaA
• EUROSETS S.R.L.
• F. Hoffmann-La Roche Ltd.
• Fisher & Paykel Healthcare Corporation Limited
• GE HealthCare
• Getinge AB
• Hamilton Medical AG
• HEALIOS K.K.
• LivaNova PLC
• Novartis AG
• NRx Pharmaceuticals
• Pfizer Inc.
• Sun Pharmaceutical Industries Limited
• Terumo Medical Corporation
• United Therapeutics Corporation
• WEINMANN Emergency Medical Technology GmbH+Co. KG

LIST OF FIGURES

• FIGURE 1. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET RESEARCH PROCESS
• FIGURE 2. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET DYNAMICS
• TABLE 7. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIRECT LUNG INJURY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INDIRECT LUNG INJURY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 28. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 45. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 48. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 80. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 100. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 112. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 115. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 144. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

The Acute Respiratory Distress Syndrome Market was valued at USD 2.56 billion in 2023, expected to reach USD 2.72 billion in 2024, and is projected to grow at a CAGR of 6.13%, to USD 3.89 billion by 2030.

Acute Respiratory Distress Syndrome (ARDS) is a severe and rapid-onset respiratory condition characterized by widespread inflammation in the lungs. It leads to a reduced ability to oxygenate the blood, often requiring critical care support, such as mechanical ventilation. The necessity of addressing ARDS stems from its high mortality rate and the increasing prevalence of respiratory conditions globally. The application of ARDS research and treatment spans across healthcare facilities, with the primary end-users being hospitals and specialized respiratory care centers. Recent market insights emphasize the growing demand for advanced ventilation equipment, innovative pharmacological therapies, and supportive care products, driven by the aging population and rising incidence of chronic lung diseases. Key growth influencers include technological advancements in medical devices, increased healthcare expenditure, and improving healthcare infrastructures in emerging economies. Notably, the COVID-19 pandemic has heightened awareness and investment in respiratory care, presenting significant opportunities in telemedicine and remote monitoring solutions for ARDS management.

Opportunities lie in the development of personalized medicine approaches and biologics, which offer potential breakthroughs in individual patient management. However, the market faces limitations such as high treatment costs, regulatory hurdles, and the complexity of ARDS pathophysiology, which poses challenges for developing universally effective therapies. There is also a critical need for improved diagnostic tools to ensure early detection and intervention. Areas ripe for innovation include non-invasive ventilation techniques, early-stage ARDS biomarkers, and AI-driven predictive analytics for patient outcomes. The ARDS market is dynamic, with a trend towards integration of digital health technologies and collaborations among biotech companies, research institutions, and healthcare providers. To capitalize on this, businesses should focus on strategic partnerships and invest in research for novel therapeutic solutions. Addressing the socio-economic barriers and enhancing patient awareness will also help in fortifying market presence and growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Respiratory Distress Syndrome Market

The Acute Respiratory Distress Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections
  • Advancements in mechanical ventilation and supportive therapies
  • Rising focus on research and development of new pharmaceuticals
• Market Restraints
  • High treatment costs and limited accessibility to advanced care
• Market Opportunities
  • Ongoing development of personalized medicine approaches
  • Increasing government initiatives and healthcare infrastructure investments
• Market Challenges
  • Regulatory complexities for the approval of new therapies and devices

Porter's Five Forces: A Strategic Tool for Navigating the Acute Respiratory Distress Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Respiratory Distress Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Respiratory Distress Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Respiratory Distress Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Respiratory Distress Syndrome Market

A detailed market share analysis in the Acute Respiratory Distress Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Respiratory Distress Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Respiratory Distress Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Respiratory Distress Syndrome Market

A strategic analysis of the Acute Respiratory Distress Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Respiratory Distress Syndrome Market, highlighting leading vendors and their innovative profiles. These include APEPTICO GmbH, Armstrong Medical Ltd., Athersys, Inc., Bayer AG, Besmed Health Business Corp., Dragerwerk AG & Co. KGaA, EUROSETS S.R.L., F. Hoffmann-La Roche Ltd., Fisher & Paykel Healthcare Corporation Limited, GE HealthCare, Getinge AB, Hamilton Medical AG, HEALIOS K.K., LivaNova PLC, Novartis AG, NRx Pharmaceuticals, Pfizer Inc., Sun Pharmaceutical Industries Limited, Terumo Medical Corporation, United Therapeutics Corporation, and WEINMANN Emergency Medical Technology GmbH + Co. KG.

Market Segmentation & Coverage

This research report categorizes the Acute Respiratory Distress Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Diagnostics and Treatment.
• Based on Cause, market is studied across Direct Lung Injury and Indirect Lung Injury.
• Based on End-user, market is studied across Hospital and Speciality Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections
    • 5.1.1.2. Advancements in mechanical ventilation and supportive therapies
    • 5.1.1.3. Rising focus on research and development of new pharmaceuticals
  • 5.1.2. Restraints
    • 5.1.2.1. High treatment costs and limited accessibility to advanced care
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing development of personalized medicine approaches
    • 5.1.3.2. Increasing government initiatives and healthcare infrastructure investments
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory complexities for the approval of new therapies and devices
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Increasing need for diagnostics due to its potential for precision medicine application
  • 5.2.2. End-user: Expanding preference for hospitals for management of ARDS
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Acute Respiratory Distress Syndrome Market, by Type

• 6.1. Introduction
• 6.2. Diagnostics
• 6.3. Treatment

7. Acute Respiratory Distress Syndrome Market, by Cause

• 7.1. Introduction
• 7.2. Direct Lung Injury
• 7.3. Indirect Lung Injury

8. Acute Respiratory Distress Syndrome Market, by End-user

• 8.1. Introduction
• 8.2. Hospital
• 8.3. Speciality Clinics

9. Americas Acute Respiratory Distress Syndrome Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Acute Respiratory Distress Syndrome Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Acute Respiratory Distress Syndrome Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. BioAegis scores USD 20millon BARDA contract to develop ARDS therapy
  • 12.3.2. Veru Inc., Reaches Agreement With FDA on a New Phase III Clinical Trial for Sabizabulin for Broader Indication Hospitalized Adult Patients with any Type of Viral Acute Respiratory Distress Syndrome ARDS
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. APEPTICO GmbH
• 2. Armstrong Medical Ltd.
• 3. Athersys, Inc.
• 4. Bayer AG
• 5. Besmed Health Business Corp.
• 6. Dragerwerk AG & Co. KGaA
• 7. EUROSETS S.R.L.
• 8. F. Hoffmann-La Roche Ltd.
• 9. Fisher & Paykel Healthcare Corporation Limited
• 10. GE HealthCare
• 11. Getinge AB
• 12. Hamilton Medical AG
• 13. HEALIOS K.K.
• 14. LivaNova PLC
• 15. Novartis AG
• 16. NRx Pharmaceuticals
• 17. Pfizer Inc.
• 18. Sun Pharmaceutical Industries Limited
• 19. Terumo Medical Corporation
• 20. United Therapeutics Corporation
• 21. WEINMANN Emergency Medical Technology GmbH + Co. KG